Table 3.
Adjusted odds ratios (95% confidence intervals) of colon and rectal cancer by quartile levels of plasma saturated and monounsaturated fatty acids (MUFA) and their desaturase indices, the Singapore Chinse Health Studya
1st (low) | 2nd | 3rd | 4th (high) | P trend | |
---|---|---|---|---|---|
Colon cancer | |||||
Saturated fatty acids | |||||
Palmitic acid (16:0) | 1.00 (Referent) | 0.77 (0.40–1.49) | 0.71 (0.37–1.36) | 0.41 (0.20–0.83) | 0.016 |
Stearic acid (18:0) | 1.00 (Referent) | 0.97 (0.55–1.69) | 0.96 (0.56–1.64) | 0.55 (0.30–0.99) | 0.070 |
MUFAs | |||||
Palmitoleic acid (16:1) | 1.00 (Referent) | 0.79 (0.44–1.42) | 0.81 (0.46–1.41) | 0.51 (0.28–0.95) | 0.051 |
Oleic acid (18:1) | 1.00 (Referent) | 0.56 (0.30–1.04) | 0.69 (0.37–1.28) | 0.39 (0.20–0.76) | 0.015 |
Stearoyl-coenzyme A desaturase (SCD)-1 indices | |||||
Palmitoleic:Palmitic acid ratio | 1.00 (Referent) | 0.79 (0.43–1.44) | 0.93 (0.54–1.59) | 0.58 (0.31–1.08) | 0.165 |
Oleic:Stearic acid ratio | 1.00 (Referent) | 0.79 (0.41–1.51) | 0.58 (0.28–1.23) | 0.42 (0.19–0.92) | 0.024 |
Rectal cancer | |||||
Saturated fatty acids | |||||
Palmitic acid (16:0) | 1.00 (Referent) | 0.92 (0.46–1.83) | 1.15 (0.55–2.44) | 1.50 (0.65–3.44) | 0.312 |
Stearic acid (18:0) | 1.00 (Referent) | 1.55 (0.78–3.09) | 0.84 (0.39–1.82) | 1.72 (0.79–3.75) | 0.356 |
MUFAs | |||||
Palmitoleic acid (16:1) | 1.00 (Referent) | 0.81 (0.40–1.62) | 0.98 (0.50–1.90) | 1.10 (0.51–2.39) | 0.768 |
Oleic acid (18:1) | 1.00 (Referent) | 1.70 (0.86–3.36) | 1.43 (0.68–3.01) | 1.77 (0.80–3.91) | 0.219 |
SCD-1 indices | |||||
Palmitoleic:Palmitic acid ratio | 1.00 (Referent) | 0.90 (0.45–1.80) | 1.12 (0.49–2.58) | 1.09 (0.50–2.36) | 0.743 |
Oleic:Stearic acid ratio | 1.00 (Referent) | 1.54 (0.76–3.12) | 1.26 (0.62–2.58) | 1.15 (0.48–2.76) | 0.730 |
a Odds ratios are adjusted for body mass index (<20, 20–24, 24–28, ≥28 kg/m2), smoking (never, light, heavy), education level (none, primary, ≥secondary), alcohol use (none, <7, ≥7 drinks/week), weekly physical activity (yes, no), history of diabetes (yes, no), and use of nonsteroidal anti-inflammatory drugs (NSAIDs) (yes, no)